Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells

Nanomedicine

Volumn 10, Issue 1, 2015, Pages 143-160

  Krishnamurthy, Sangeetha ^a,b   Ke, Xiyu ^a,b   Yang, Yi Yan ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer stem cells; cancer therapy; drug delivery; gene delivery; nanocarriers; protein delivery

Indexed keywords

NANOCARRIER; NANOPARTICLE;

CANCER CELL; CANCER RECURRENCE; CANCER STEM CELL; CANCER THERAPY; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; CHEMISTRY; DRUG EFFECTS; HUMAN; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84921491505     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.154     Document Type: Review

References (143)

1. Velasco-Velázquez MA, Homsi N, De La Fuente M, Pestell RG. Breast cancer stem cells. Int. J. Biochem. Cell Biol. 44(4), 573-577 (2012).
2. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
3. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3), 504-514 (2007).
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23), 10946-10951 (2005).
5. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
6. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67(3), 1030-1037 (2007).
7. Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J. Clin. Oncol. 26(17), 2876-2882 (2008).
8. Takaishi S, Okumura T, Tu S et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5), 1006-1020 (2009).
9. Zhou L, Wei X, Cheng L, Tian J, Jiang JJ. CD133, one of the markers of cancer stem cells in Hep2 cell line. Laryngoscope 117(3), 455-460 (2007).
10. Hirschmann-Jax C, Foster A, Wulf G et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101(39), 14228-14233 (2004).
11. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 103(30), 11154-11159 (2006).
12. Abubaker K, Latifi A, Luwor R et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer 12(1), 24 (2013).
13. Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer 118(13), 3225-3225 (2012).
14. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5(4), 275-284 (2005).
15. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
16. Riccioni R, Dupuis ML, Bernabei M et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol. Dis. 45(1), 86-92 (2010).
17. Milane L, Duan Z, Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 6(9), e24075 (2011).
18. KüHnle M, Egger M, MüLler C et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 52(4), 1190-1197 (2009).
19. Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E. Preferential killing of breast tumor initiating cells by N, N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine/ tesmilifene. Clin. Cancer Res. 15(1), 119-130 (2009).
20. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69(19), 7507-7511 (2009).
21. Kakarala M, Brenner DE, Korkaya H et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 122(3), 777-785 (2010).
22. Chen D, Pamu S, Cui Q, Chan TH, Dou QP. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg. Med. Chem. 20(9), 3031-3037 (2012).
23. Li Y, Zhang T, Korkaya H et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 16(9), 2580-2590 (2010).
24. Abraham J, Edgerly M, Wilson R et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res. 15(10), 3574-3582 (2009).
25. Pusztai L, Wagner P, Ibrahim N et al. Phase II study of tariquidar, a selective Pglycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4), 682-691 (2005).
26. Martin-Castillo B, Dorca J, Vazquez-Martin A et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann. Oncol. 21(1), 187-189 (2010).
27. Kim J, Lim W, Kim E-K et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer 14(1), 170 (2014).
28. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4(6), 807-818 (2007).
29. Boehmerle W, Endres M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis. 2(6), e168 (2011).
30. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad. Med. J. 80(942), 239-240 (2004).
31. Mcguinness M, Talbert R. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann. Pharmacother. 27(10), 1183-1187 (1993).
32. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
33. Zhu H, Chen H, Zeng X et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 35(7), 2391-2400 (2014).
34. Li Y, Wang F, Sun T, Du J, Yang X, Wang J. Surface-modulated and thermoresponsive polyphosphoester nanoparticles for enhanced intracellular drug delivery. Sci. China Chem. 57(4), 1-7 (2014).
35. Lei C, Cui Y, Zheng L, Kah-Hoe Chow P, Wang C-H. Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects. Biomaterials 34(30), 7483-7494 (2013).
36. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25(4), 427-437 (2005).
37. Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv. Funct. Mat. 19(10), 1553-1566 (2009).
38. Tan YF, Mundargi RC, Chen MHA et al. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Small 10(9), 1790-1798 (2014).
39. Mccarron PA, Marouf WM, Quinn DJ et al. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug. Chem. 19(8), 1561-1569 (2008).
40. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2), 358-365 (2010).
41. Yuan YY, Mao CQ, Du XJ, Du JZ, Wang F, Wang J. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv. Mater. 24(40), 5476-5480 (2012).
42. Hamaguchi T, Matsumura Y, Suzuki M et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92(7), 1240-1246 (2005).
43. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 6(4), 715-728 (2011).
44. Li YY, Cheng H, Zhu JL et al. Temperature and pH-sensitive multicolored micellar complexes. Adv. Mater. 21(23), 2402-2406 (2009).
45. Du J-Z, Du X-J, Mao C-Q, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 133(44), 17560-17563 (2011).
46. Soppimath KS, Tan DW, Yang YY. pH-triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Adv. Mater. 17(3), 318-323 (2005).
47. Li Y-Y, Hua S-H, Xiao W et al. Dual-vectors of anti-cancer drugs and genes based on pH-sensitive micelles self-assembled from hybrid polypeptide copolymers. J. Mater. Chem. 21(9), 3100-3106 (2011).
48. Gao Z-G, Tian L, Hu J, Park I-S, Bae YH. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J. Control. Release 152(1), 84-89 (2011).
49. Lee SJ, Koo H, Lee D-E et al. Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. Biomaterials 32(16), 4021-4029 (2011).
50. Wiradharma N, Zhang Y, Venkataraman S, Hedrick JL, Yang YY. Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today 4(4), 302-317 (2009).
51. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1), 271-284 (2000).
52. Liu S-Q, Wiradharma N, Gao S-J, Tong YW, Yang Y-Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 28(7), 1423-1433 (2007).
53. Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30(5), 919-927 (2009).
54. Kim D, Jeong YY, Jon S. A drug-loaded aptamer? gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4(7), 3689-3696 (2010).
55. Wilson BJ, Schatton T, Zhan Q et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 71(15), 5307-5316 (2011).
56. Blanpain C, Mohrin M, Sotiropoulou PA, Passegué E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8(1), 16-29 (2011).
57. Sachlos E, Risueño RM, Laronde S et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149(6), 1284-1297 (2012).
58. Wang Y-C, Chao T-K, Chang C-C, Yo Y-T, Yu M-H, Lai H-C. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS ONE 8(9), e74538 (2013).
59. Bednar F, Simeone DM. Metformin and cancer stem cells: old drug, new targets. Cancer Prev. Res. (Philadelphia) 5(3), 351-354 (2012).
60. Wang K, Zhang T, Liu L et al. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int. J. Nanomedicine 7, 4487 (2012).
61. Zhang L, Li L, Jiao M et al. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Cancer Lett. 323(1), 48-57 (2012).
62. Perlstein B, Finniss SA, Miller C et al. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol. 15(1), 29-40 (2013).
63. Datta J, Smith A, Lang JC et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C&epsiv. Oncogene 31(36), 4045-4053 (2011).
64. Barenholz YC. Doxil® - the first FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117-134 (2012).
65. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100(4), 572-579 (2009).
66. Wang K, Liu L, Zhang T et al. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int. J. Nanomedicine 6, 3207 (2011).
67. Liu Y, Lu W-L, Guo J et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 129(1), 18-25 (2008).
68. Guo J, Lu W-L. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J. Pharm. Pharm. Sci. 13(2), 136-151 (2010).
69. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 33(2), 679-691 (2012).
70. Ke X-Y, Lin Ng VW, Gao S-J, Tong YW, Hedrick JL, Yang YY. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 35(3), 1096-108 (2013).
71. Ebrahim Attia AB, Yang C, Tan JP et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials 34(12), 3132-3140 (2013).
72. Li R-J, Ying X, Zhang Y et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release 149(3), 281-291 (2011).
73. Pratt RC, Nederberg F, Waymouth RM, Hedrick JL. Tagging alcohols with cyclic carbonate: a versatile equivalent of (meth) acrylate for ring-opening polymerization. Chem. Commun. (1), 114-116 (2008).
74. Pratt RC, Lohmeijer BG, Long DA et al. Exploration, optimization, and application of supramolecular thiourea-amine catalysts for the synthesis of lactide (co) polymers. Macromolecules 39(23), 7863-7871 (2006).
75. Yang C, Tan JP, Cheng W et al. Supramolecular nanostructures designed for high cargo loading capacity and kinetic stability. Nano Today 5(6), 515-523 (2010).
76. Kim SH, Tan JP, Fukushima K et al. Thermoresponsive nanostructured polycarbonate block copolymers as biodegradable therapeutic delivery carriers. Biomaterials 32(23), 5505-5514 (2011).
77. Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5(4), 496-504 (2008).
78. Khan M, Ong ZY, Wiradharma N, Attia ABE, Yang YY. Advanced materials for co-delivery of drugs and genes in cancer therapy. Adv. Healthc. Mater. 1(4), 373-392 (2012).
79. Piao L, Zhang M, Datta J et al. Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 20(6), 1261-1269 (2012).
80. Liu C, Kelnar K, Liu B et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17(2), 211-215 (2011).
81. Shi S, Han L, Gong T, Zhang Z, Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. Engl. 52(14), 3901-3905 (2013).
82. Iorio MV, Ferracin M, Liu C-G et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005).
83. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699-8707 (2007).
84. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137(4), 647-658 (2009).
85. Yang Y-P, Chien Y, Chiou G-Y et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33(5), 1462-1476 (2012).
86. Chiou G-Y, Cherng J-Y, Hsu H-S et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 159(2), 240-250 (2012).
87. Liu C, Zhao G, Liu J et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 140(3), 277-283 (2009).
88. Kato T, Natsume A, Toda H et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17(11), 1363-1371 (2010).
89. Liu Q, Li R-T, Qian H-Q et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 34(29), 7191-7203 (2013).
90. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8(2), 97-106 (2011).
91. Beh CW, Seow WY, Wang Y et al. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10(1), 41-48 (2008).
92. Dou J, He X, Liu Y et al. Targeted therapeutic effect of anti-ABCG2 antibody combined with nano silver and vincristine on mouse myeloma cancer stem cells. J. Nanopart. Res. 15(12), 1-12 (2013).
93. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120(2), 485 (2010).
94. Ma X, Xi L, Luo D et al. Anti-tumor effects of the peptide TMTP1-GG-D (KLAKLAK) 2 on highly metastatic cancers. PLoS ONE 7(9), e42685 (2012).
95. Mcclements L, Yakkundi A, Papaspyropoulos A et al. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin. Cancer Res. 19(14), 3881-3893 (2013).
96. Piotrowicz RS, Damaj BB, Hachicha M, Incardona F, Howell SB, Finlayson M. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol. Cancer Ther. 10(11), 2072-2082 (2011).
97. Bertrand G, Maalouf M, Boivin A et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev. 10(1), 114-126 (2014).
98. Moon CM, Kwon JH, Kim JS et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int. J. Cancer 134(3), 519-529 (2014).
99. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 17(1), 71-80 (2012).
100. Bisht S, Feldmann G, Soni S et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5(3), 1-18 (2007).
101. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 11(5), 464-473 (2011).
102. Zhang L, Yao H-J, Yu Y et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 33(2), 565-582 (2012).
103. Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur. J. Cancer 49(15), 3210-3218 (2013).
104. Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25(10), 2524-2533 (2007).
105. Mueller MT, Hermann PC, Witthauer J et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137(3), 1102-1113 (2009).
106. Goff DJ, Recart AC, Sadarangani A et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12(3), 316-328 (2013).
107. Yuan P, Ito K, Perez-Lorenzo R et al. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc. Natl Acad. Sci. USA 110(45), 18226-18231 (2013).
108. Herpel E, Jensen K, Muley T et al. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res. 31(12), 4491-4500 (2011).
109. Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med. Oncol. 28(4), 1458-1462 (2011).
110. Liu S, Wicha MS. Targeting breast cancer stem cells. J. Clin. Oncol. 28(25), 4006-4012 (2010).
111. Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7(9), 1028-1034 (2001).
112. Dick JE. Breast cancer stem cells revealed. Proc. Natl Acad. Sci. USA 100(7), 3547-3549 (2003).
113. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 451(7176), 345-349 (2008).
114. Zimmerer RM, Korn P, Demougin P et al. Functional features of cancer stem cells in melanoma cell lines. Cancer Cell Int. 13(1), 78 (2013).
115. Civenni G, Walter A, Kobert N et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71(8), 3098-3109 (2011).
116. Jiang Y, He Y, Li H et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer 15(4), 440-450 (2012).
117. Jiang J, Zhang Y, Chuai S et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 31(6), 671-682 (2012).
118. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138(6), 2151-2162 (2010).
119. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon cancer stem cells. J. Mol. Med. 87(11), 1097-1104 (2009).
120. Hosen N, Park CY, Tatsumi N et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(26), 11008-11013 (2007).
121. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15(9), 494-501 (2005).
122. Jin L, Lee EM, Ramshaw HS et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor - chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1), 31-42 (2009).
123. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J. Clin. Oncol. 26(17), 2806-2812 (2008).
124. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int. J. Biol. Sci. 7(5), 517-535 (2011).
125. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J. Clin. Invest. 123(5), 1911-1918 (2013).
126. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat. Rev. Cancer 6(6), 425-436 (2006).
127. Mao X-G, Zhang X, Xue X-Y et al. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl. Oncol. 2(4), 247 (2009).
128. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J. Cell. Biochem. 108(5), 1031-1038 (2009).
129. Yang Y, Chang J. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 26(7), 725-733 (2008).
130. Huang P, Watanabe M, Kaku H et al. Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line. Mol. Clin. Oncol. 1(1), 180-184 (2013).
131. N Tran M, Jinesh G, J McConkey D, M Kamat A. Bladder cancer stem cells. Curr. Stem Cell Res. Ther. 5(4), 387-395 (2010).
132. Silva IA, Bai S, Mclean K et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71(11), 3991-4001 (2011).
133. Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10(2), 325-335 (2011).
134. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur. J. Cancer 42(9), 1213-1218 (2006).
135. Lang S, Frame F, Collins A. Prostate cancer stem cells. J. Pathol. 217(2), 299-306 (2009).
136. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3), 504-514 (2008).
137. Ailles L, Prince M. Cancer stem cells in head and neck squamous cell carcinoma. Cancer Stem Cells 175-193 (2009).
138. Krishnamurthy S, Nör J. Head and neck cancer stem cells. J. Dent. Res. 91(4), 334-340 (2012).
139. Prince M, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104(3), 973-978 (2007).
140. Feng D, Peng C, Li C et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol. Rep. 22(5), 1129-1134 (2009).
141. Zhang S-L, Wang Y-S, Zhou T, Yu X-W, Wei Z-T, Li Y-L. Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology 64(4), 477-484 (2012).
142. Yu L, Yang L, An W, Su X. Anticancer bioactive peptide-3 inhibits human gastric cancer growth by suppressing gastric cancer stem cells. J. Cell. Biochem. 115(4), 697-711 (2014).
143. Zubeldia IG, Bleau A-M, Redrado M et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGF-1-targeting peptides P17 and P144. Exp. Cell. Res. 319(3), 12-22 (2013).